Enzychem’s partnerships involve the joint work with various institutions around the world.
- ASAN Medical Center
Since its establishment in June, 1989, the ASAN Medical Center has grown to become the largest medical institution in Korea, and has achieved a world-class medical reputation, notably for their investment in R&D and clinical treatments. With the mission of pursuing optimal human health with unwavering passion, and delivering high quality care to all patients, the South Korean medical institute returns its profits back to society and fulfills its founding spirit through free medical services for the less privileged neighbors. Furthermore, the ASAN Medical Center does not only lend its mission to patients in South Korea, but to those from all over the world. Its numerous partnerships with hospitals and research institutes include those from the U. S., the U. K., and nations all across East and Southeast Asia. Dr. Myung Hwan Kim of Asan Medical Center is a member of Enzychem Lifesciences’ Board of Directors, and currently leads the clinical development of EC-18.
What was originally established as a Genetic Engineering Research Center in 1985, KRIBB (Korea Research Institute of Bioscience and Biotechnology) now stands as the only government research institute in South Korea dedicated to biotechnology research across a broad span of expertise, including new drug discovery. KRIBB’s mission extends beyond the national scheme, and strives to carry out R&D and other relevant projects within the field of bioscience and biotechnology in joint effort with other research institutes, academia, and businesses at home and abroad. The research institute’s project with Enzychem in debuting EC-18 to the U. S. market is only partially exemplary of its global network that spans all over Europe, the Americas, and all of Asia. Dr. Jae Wha Kim of KRIBB leads Enzychem Lifesciences’ non-clinical studies and is responsible for conducting EC-18’s MoA (Mechanism of Action) study.